Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.
Ruchir RamanVarun RamamohanAnurag RathoreDeepali JainAnant MohanVishal VashisthaPublished in: Asia-Pacific journal of clinical oncology (2022)
Nearly 40% of Indian patients with advanced adenocarcinoma and 30% with NSCLC share an actionable mutation in ALK or EGFR. Approximately one-half of adenocarcinoma patients have an actionable variant. Efforts should be directed toward efficiently identifying candidates for targeted agents and delivering such treatments.